Text Size
3005 studies found for:    novartis

Modify this search | How to Use Search Results

Show Display Options
Download search resultsDownload the search results for:
novartis (3005 records)
Need help? See Downloading Content for Analysis
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed
Has Results 		A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
Conditions: Meningococcal Meningitis;   Meningococcal Infections
Interventions: Biological: Meningococcal ACWY Polysaccharide Vaccine;   Biological: MenACWY CRM (19 to 55 years);   Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: Novartis MenACWY Vaccine (56 to 65 Years)
2 Not yet recruiting Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Condition: Neoplasms
Interventions: Drug: Everolimus;   Drug: Sandostatin LAR Depot
3 Completed Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
Condition: Meningococcal Disease
Intervention: Biological: Serogroup B meningococcal Vaccine
4 Completed
Has Results 		A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
Conditions: Meningococcal Meningitis;   Human Papillomavirus Infection;   Pertussis;   Tetanus
Interventions: Biological: Novartis Meningococcal ACWY Conjugate Vaccine;   Biological: Tdap Vaccine
5 Completed
Has Results 		A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
Conditions: Meningococcal Infections;   Meningococcal Meningitis
Interventions: Biological: MenACWY CRM;   Biological: Meningococcal ACWY Conjugate vaccine
6 Completed
Has Results 		Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM;   Biological: Licensed meningococcal ACWY vaccine
7 Completed B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-Hib_IPV;   Biological: PCV;   Biological: MMR;   Biological: Hib
8 Recruiting Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Condition: GIST and CML
Intervention: Drug: AMN107
9 Completed Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg
Condition: Healthy
Interventions: Drug: CJ Amlodipine/Valsartan 10/160mg;   Drug: Novartis Exforge 10/160mg
10 Not yet recruiting Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: GIST and CML
Intervention: Drug: STI571
11 Completed Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Intervention: Biological: Meningococcal C conjugate vaccine
12 Completed
Has Results 		Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
Condition: Meningococcal Disease
Interventions: Biological: Men ACWY CRM;   Biological: 4CMenB
13 Not yet recruiting Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: Hematologic Neoplasms
Intervention: Drug: Panobinostat
14 Completed Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet
Condition: Healthy
Intervention: Drug: CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg
15 Not yet recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease,;   Acromegaly,;   Neuroendocrine Tumors,;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors,;   Dumping Syndrome,;   Prostate Cancer,;   Melanoma Negative for bRAF,;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
16 Completed Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
Condition: Meningococcal Meningitis
Interventions: Other: Blood draw;   Biological: Group IV;   Biological: Group V
17 Completed Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
Condition: Influenza
Intervention: Other: Non-intervention observational study
18 Completed Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Intervention: Biological: Meningococcal vaccines
19 Not yet recruiting Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-risk Adults
Conditions: Meningococcal Disease,;   Meningococcal Meningitis,;   Prevention Vaccination
Intervention: Biological: Recombinant Meningococcal B + Outer Membrane Vesicle New Zealand Vaccine
20 Completed
Has Results 		Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM + MMRV;   Biological: MMRV;   Biological: MenACWY-CRM
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years